AR055287A1 - Inhibidores de la dimerizacion de la sintasa inducible por oxido nitrico ,composiciones farmaceuticas - Google Patents
Inhibidores de la dimerizacion de la sintasa inducible por oxido nitrico ,composiciones farmaceuticasInfo
- Publication number
- AR055287A1 AR055287A1 ARP050104970A ARP050104970A AR055287A1 AR 055287 A1 AR055287 A1 AR 055287A1 AR P050104970 A ARP050104970 A AR P050104970A AR P050104970 A ARP050104970 A AR P050104970A AR 055287 A1 AR055287 A1 AR 055287A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- heteroaryl
- independently selected
- haloalkoxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000006471 dimerization reaction Methods 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000003107 substituted aryl group Chemical group 0.000 abstract 5
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 150000001336 alkenes Chemical class 0.000 abstract 3
- 150000001345 alkine derivatives Chemical class 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Composiciones farmacéuticas que comprenden dichos compuestos. Reivindicacion 1: Un compuesto de la formula (1) o una sal, éster, o profármaco de esto, caracterizado porque: T, V, X, y Y se seleccionan independientemente del grupo que consiste en CR4 y N; Z es del grupo que consiste en CR3 y N; W y W' se seleccionan independientemente del grupo que consiste en CH2, CR7R8, NR9, O, N(O), S(O)q, y C(O); q es 0, 1, o 2; R3, R4, R10, R14, R15, R16, R17 y R18 se seleccionan independientemente del grupo que consiste en hidrogeno, halogeno, alquilo opcionalmente sustituido, y haloalquilo, haloalcoxi opcionalmente sustituido, aralquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaralquilo opcionalmente sustituido, alqueno opcionalmente sustituido, alquino opcionalmente sustituido; o R14 y R15 pueden formar junto un carbonilo, carbociclo opcionalmente sustituido o heterociclo opcionalmente sustituido; o R14 y R15 juntos se pueden anular, formando un enlace adicional; R5, R6, R7, R8, y R9 se seleccionan independientemente del grupo que consiste en hidrogeno, halogeno, alquilo opcionalmente sustituido, alcoxi opcionalmente sustituido, haloalquilo, haloalcoxi, aralquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroalquilo opcionalmente sustituido, alqueno opcionalmente sustituido, alquino opcionalmente sustituido, -(O)N(R11)R12, -P(O)[N(R11)R12]2, - SO2NHC(O)R11, - N(R11)SO2R12, -SO2N(R11)R12, -NSO2N(R11)R12, -C(O)NHSO2R11, -CH=NOR11, -OR11, - S(O)t-R11, -N(R11)R12, - N(R11)C(O)N(R12)R13, - N(R11)C(O)OR12, -N(R11)C(O)R12, -[C(R14)R15]r-R12, -[C(R14)R15]r-C(O)OR11, -[C(R14)R15]r-[C(O)OR11]2, - [C(R14)R15]rC(O)N(R11)R12, -[C(R14)R15]r-N(R11)R12, -[C(R14)R15]r-N(R11-[C(R14)R15]rR12, -[C(R14)R15]r-OR11, -N(R11)-[C(R14)R15]r-R12, -N(R11)C(O)N(R13)-[C(R14)R15]r-R12, -C(O)-[C(R14)R15]r-N(R11)R12, -N(R13)C(O)-L-(R11)R12, -N(R11)-[C(R14)R15]r-L- R12, -N(R11)C(O)N(R11)-[C(R14)R15]r-L-R12, -[C(R14)R15]r-L-R12, y -L-C(O)N(R11)R12; o R5 y R6 juntos pueden formar un arilo opcionalmente sustituido, un heteroarilo opcionalmente sustituido, un cicloalquilo opcionalmente sustituido, o un heterocicloalquilo opcionalmente sustituido; t es un numero entero de 0 a 2; r es un numero entero de 0 a 5; L se selecciona del grupo que consiste en un grupo carbocíclico de 3- a 7-miembros opcionalmente sustituidos, un grupo heterocíclico con 3- a 7-miembros opcionalmente sustituido, un grupo con 6 miembros opcionalmente sustituidos, y un grupo heteroarilo con 6-miembros opcionalmente sustituido; R11, R12, y R13 se seleccionan independientemente del grupo que consiste en hidrogeno, halogeno, alquilo opcionalmente sustituido, haloalquilo, haloalcoxi, aralquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroalquilo opcionalmente sustituido, alqueno opcionalmente sustituido, alquino opcionalmente sustituido, -OR17, -S(O)tR17, -[C(R14)R15]r-C(O)OR17, -[C(R14)R15]r-N(R17)R18, -[C(R14)R15]r-N(R16)C(O)N(R17)R18, -[C(R14)R15]r-N(R17)C(O)OR18, -[C(R14)R15]r-R17, y -[C(R14)R15]-N(R17)C(O)R18; o R11 o R12 puede definirse por medio de una estructura seleccionada del grupo la cual consiste en las formulas (2) y (3), donde: u y v son independientemente un numero entero de 0 a 3; y X1 y X2 se seleccionan del grupo que consiste en hidrogeno, halogeno, hidroxi, aciloxi inferior, alquilo inferior opcionalmente sustituido, alcoxi inferior opcionalmente sustituido, haloalquilo inferior, haloalcoxi inferior, y perhaloalquilo inferior; o X1 y X2 juntos pueden formar un arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, o heterocicloalquilo opcionalmente sustituido; y siempre que: cuando Z, T y Y son cada uno un CR4, entonces X no es N; al menos uno de Z, T, Y, o X es N; y el sustituyente de anillo con 6-miembros formado por el resto de formula (4) no es parte de 5,6,7,8-tetrahidropirido[3,4-d]pirimidina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63197104P | 2004-12-01 | 2004-12-01 | |
| US67200105P | 2005-04-14 | 2005-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055287A1 true AR055287A1 (es) | 2007-08-15 |
Family
ID=36215758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104970A AR055287A1 (es) | 2004-12-01 | 2005-11-28 | Inhibidores de la dimerizacion de la sintasa inducible por oxido nitrico ,composiciones farmaceuticas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7825256B2 (es) |
| EP (1) | EP1817030A2 (es) |
| JP (1) | JP2008521908A (es) |
| KR (1) | KR20070084574A (es) |
| AR (1) | AR055287A1 (es) |
| AU (1) | AU2005311985A1 (es) |
| BR (1) | BRPI0518096A (es) |
| CA (1) | CA2589433A1 (es) |
| IL (1) | IL183392A0 (es) |
| TW (1) | TW200635587A (es) |
| WO (1) | WO2006060424A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070123572A1 (en) * | 2005-11-28 | 2007-05-31 | Kalypsys, Inc. | Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines |
| WO2007062417A1 (en) * | 2005-11-28 | 2007-05-31 | Kalypsys, Inc. | Methods of preparing 2-imidazol-1-yl-4-methyl-6-pyrrolidin-2-yl-pyrimidine and 4-(1-alkylpyrrolidin-2-yl)-2-(1h-imidazol-1-yl)-6-methylpyrimidine derivatives |
| EP1954694A1 (en) * | 2005-11-28 | 2008-08-13 | Kalypsys, Inc. | Imidazole derivatives as nitric oxide synthase dimerisation inhibitor |
| FR2903405B1 (fr) * | 2006-07-04 | 2011-09-09 | Pasteur Institut | Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications |
| US20100055071A1 (en) * | 2006-11-21 | 2010-03-04 | Martin Robert Leivers | Anti-Viral Compounds |
| EP1939181A1 (en) * | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
| WO2008086176A2 (en) * | 2007-01-08 | 2008-07-17 | Kalypsys, Inc. | Topical pharmaceutical formulation comprising an inos inhibitor for the treatment of disease |
| US20100311776A1 (en) * | 2008-01-30 | 2010-12-09 | Smithkline Beecham Corporation | Novel sEH Inhibitors and their Use |
| US20100324076A1 (en) * | 2008-01-30 | 2010-12-23 | Joseph Paul Marino | Novel sEH Inhibitors and their Use |
| US8578892B2 (en) * | 2008-06-13 | 2013-11-12 | Air Products And Chemicals, Inc. | Oxygen control system for oxygen enhanced combustion of solid fuels |
| US8478446B2 (en) | 2008-06-13 | 2013-07-02 | Air Products And Chemicals, Inc. | Oxygen control system for oxygen enhanced combustion |
| JP2015180606A (ja) * | 2012-08-01 | 2015-10-15 | アステラス製薬株式会社 | 抗癌剤の併用による癌治療方法 |
| KR20240157117A (ko) | 2014-04-08 | 2024-10-31 | 더 메서디스트 하스피틀 | iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도 |
| WO2016007966A2 (en) * | 2014-07-11 | 2016-01-14 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
| JP6460382B2 (ja) * | 2014-11-28 | 2019-01-30 | 株式会社豊田自動織機 | 飽和ヘテロ環含有化合物、並びにこれを用いた二次電池用電極及び二次電池、結着剤、蛍光物質 |
| GB201512635D0 (en) | 2015-07-17 | 2015-08-26 | Ucl Business Plc | Uses of therapeutic compounds |
| US11491136B2 (en) | 2017-02-14 | 2022-11-08 | Research Triangle Institute | Proline-based neuropeptide FF receptor modulators |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1161237B (it) | 1983-04-26 | 1987-03-18 | Montedison Spa | 1,4-dichetoni-insaturi ad attivita' fungicida |
| DE3433953A1 (de) * | 1984-09-15 | 1986-03-27 | A. Nattermann & Cie GmbH, 5000 Köln | Neue, eine imidazol-gruppe enthaltende 3,4-dihydro-2(1h)-pyridone und2(1h)-pyridone, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US5795905A (en) | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| DE19541146A1 (de) * | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| US5874452A (en) * | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| AU730789B2 (en) | 1996-05-31 | 2001-03-15 | Nps Pharmaceuticals, Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| DE19627310A1 (de) | 1996-06-27 | 1998-01-02 | Schering Ag | Imidazolderivate als Stickstoffmonoxid-Synthase-Inhibitoren |
| US6432947B1 (en) * | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| DK0968206T3 (da) * | 1997-02-19 | 2007-03-26 | Berlex Inc | N-heterocykliske derivater som NOS-inhibitorer |
| ID23510A (id) * | 1997-06-27 | 2000-04-27 | Bp Chem Int Ltd | Proses polimerisasi |
| US6861448B2 (en) * | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
| US20030191279A1 (en) * | 1999-08-27 | 2003-10-09 | Goldstein Steven Wayne | Urea derivatives useful as anticancer agents |
| US6723743B1 (en) * | 1999-09-28 | 2004-04-20 | Neurogen Corporation | High affinity small molecule C5a receptor modulators |
| YU23503A (sh) | 2000-09-29 | 2006-03-03 | Neurogen Corporation | Mali molekuli kao modulatori receptora c5a visokog afiniteta |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| FR2827286A1 (fr) | 2001-07-11 | 2003-01-17 | Aventis Cropscience Sa | Nouveaux composes fongicides |
| WO2003082205A2 (en) | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Compounds and methods |
| US20040014782A1 (en) | 2002-03-29 | 2004-01-22 | Krause James E. | Combination therapy for the treatment of diseases involving inflammatory components |
| IL164355A0 (en) | 2002-03-29 | 2005-12-18 | Neurogen Corp | New aryl imidazoles and related compounds as cra receptor modulators |
| KR20050033070A (ko) * | 2002-08-09 | 2005-04-08 | 아스트라제네카 에이비이 | 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸 |
| WO2004019986A1 (en) | 2002-08-29 | 2004-03-11 | Schering Aktiengesellschaft | Methods of treating acute respiratory distress syndrome |
| WO2004069846A1 (de) * | 2003-02-06 | 2004-08-19 | Basf Aktiengesellschaft | Pyrimidine, verfahren zu deren herstellung sowie deren verwendung |
| EP1954694A1 (en) * | 2005-11-28 | 2008-08-13 | Kalypsys, Inc. | Imidazole derivatives as nitric oxide synthase dimerisation inhibitor |
-
2005
- 2005-11-28 EP EP05852447A patent/EP1817030A2/en not_active Withdrawn
- 2005-11-28 AR ARP050104970A patent/AR055287A1/es unknown
- 2005-11-28 AU AU2005311985A patent/AU2005311985A1/en not_active Abandoned
- 2005-11-28 BR BRPI0518096-1A patent/BRPI0518096A/pt not_active IP Right Cessation
- 2005-11-28 TW TW094141754A patent/TW200635587A/zh unknown
- 2005-11-28 US US11/288,888 patent/US7825256B2/en not_active Expired - Fee Related
- 2005-11-28 WO PCT/US2005/043190 patent/WO2006060424A2/en not_active Ceased
- 2005-11-28 JP JP2007544442A patent/JP2008521908A/ja active Pending
- 2005-11-28 CA CA002589433A patent/CA2589433A1/en not_active Abandoned
- 2005-11-28 KR KR1020077011898A patent/KR20070084574A/ko not_active Withdrawn
-
2007
- 2007-05-24 IL IL183392A patent/IL183392A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200635587A (en) | 2006-10-16 |
| BRPI0518096A (pt) | 2008-10-28 |
| WO2006060424A3 (en) | 2007-03-29 |
| JP2008521908A (ja) | 2008-06-26 |
| EP1817030A2 (en) | 2007-08-15 |
| KR20070084574A (ko) | 2007-08-24 |
| US7825256B2 (en) | 2010-11-02 |
| IL183392A0 (en) | 2007-09-20 |
| US20060116515A1 (en) | 2006-06-01 |
| CA2589433A1 (en) | 2006-06-08 |
| WO2006060424A2 (en) | 2006-06-08 |
| AU2005311985A1 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055287A1 (es) | Inhibidores de la dimerizacion de la sintasa inducible por oxido nitrico ,composiciones farmaceuticas | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR068877A1 (es) | Derivados heterociclicos de imidazol | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
| PE20051141A1 (es) | Inhibidores de la polimerasa viral | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
| EA200970478A1 (ru) | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций | |
| NO20051411L (no) | Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
| PE20080102A1 (es) | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos | |
| AR075510A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR073116A1 (es) | Compuestos de pirrolo[2,3-d]-pirimidina moduladores de proteinquinasas cdk, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de cancer y enfermedades autoinmunes. | |
| EA200200942A1 (ru) | Фармацевтические композиции, содержащие производные 3-аминоазетидина, новые производные и способ их получения | |
| AR036905A1 (es) | Derivados del 3-azabiciclo[3.1.0]hexano, composiciones farmaceuticas que los contienen, su uso en un metodo para tratar un trastorno o afeccion en un mamifero, e intermediarios utiles para su sintesis | |
| AR051469A1 (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
| AR059176A1 (es) | Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis. | |
| PE20090151A1 (es) | Derivados de pirimidinona y metodos para su uso | |
| PE20060871A1 (es) | Compuestos de piridazinona | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR076830A1 (es) | Compuestos de carboxamidas de imidazol como moduladores de trpv3 | |
| DE602006020152D1 (de) | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |